CARsgen Therapeutics(02171.HK): CT0596 Secures NMPA IND Approval for Treatment of R/R MM
NewTimeSpace News: On August 4, 2026, CARsgen Therapeutics(02171.HK) announced that CT0596 has been granted IND approval by the NMPA for the treatment of patients with relapsed/refractory multiple myeloma.
According to the announcement, CT0596 is currently under evaluation via investigator-initiated trials (IIT) in relapsed/refractory multiple myeloma or plasma cell leukaemia. The Company also plans to further explore its application in other plasma cell neoplasms and autoimmune diseases driven by autoreactive plasma cells.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HUAJIN INTL (02738.HK): Controlling Shareholder Haiyi Places 174 Million Shares Off-Market, Stake Falls from 65.25% to 36.25%
- HUAJIN INTL (02738.HK): Notes Unusual Price Movement of Its Shares, Board Unaware of Any Cause and Operations Remain Normal
- HUAJIN INTL(02738.HK)2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 109.11 million, loss narrowed by 79.14% YoY
- Monthly Hong Kong-listed ETF Average Return Statistics (by Fund Manager) (August 2026)
- FWD (01828.HK): 2026 interim results — profit attributable to shareholders of USD 165 million, up 1550% year-on-year
